1.04

2.80% -0.03

After Hours: 1.07 0.03 +2.88%

Unicycive Therapeutics Inc (UNCY)

Overview News Price History Discussions Forecast

Unicycive Therapeutics Inc stock is currently priced at $1.04, with a 24-hour trading volume of 179.33K. It has seen a -2.80% decreased in the last 24 hours and a -29.25% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.11 pivot point. If it approaches the $1.03 support level, significant changes may occur.

Previous Close:

$1.07

Open:

$1.07

24h Volume:

179.33K

Market Cap:

$36.15M

Revenue:

Net Income/Loss:

$-30.54M

P/E Ratio:

-0.5253

EPS:

-1.98

Net Cash Flow:

$-18.30M

1W Performance:

-9.96%

1M Performance:

-29.25%

6M Performance:

+42.31%

1Y Performance:

-33.76%

1D Range:

$1.03

$1.0899

52W Range:

$0.47

$1.8227

Unicycive Therapeutics Inc Stock (UNCY) Company Profile

Name

Unicycive Therapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (688)

Phone

650 351 4495

Address

4300 El Camino Real, Suite 210, Los Altos

Employee

Twitter

Next Earnings Date

Latest SEC Filings

UNCY's Discussions on Twitter

Unicycive Therapeutics Inc Stock (UNCY) Latest News

Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

GlobeNewswire Inc.

Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire Inc.

Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress

GlobeNewswire Inc.

Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

Unicycive Announces $50 Million Private Placement

GlobeNewswire Inc.

Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference

GlobeNewswire Inc.

Unicycive Therapeutics Inc Stock (UNCY) Financials Data

Unicycive Therapeutics Inc (UNCY) Net Income 2024

UNCY net income (TTM) was -$30.54 million for the quarter ending December 31, 2023, a -69.14% decrease year-over-year.

Unicycive Therapeutics Inc (UNCY) Cash Flow 2024

UNCY recorded a free cash flow (TTM) of -$18.30 million for the quarter ending December 31, 2023, a -16.88% decrease year-over-year.

Unicycive Therapeutics Inc (UNCY) Earnings per Share 2024

UNCY earnings per share (TTM) was -$1.55 for the quarter ending December 31, 2023, a -29.17% decline year-over-year.

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.